TG Therapeutics Inc (NASDAQ:TGTX) is still cheap; has inevitable commercial success; and TGTX stock has AbbVie (NYSE:ABBV) buyout all over it.
Why ACAD stock will be the next Medivation. Pfizer, Gilead, Teva, Bristol-Myers, Otsuka & AbbVie are all companies that would want Nuplazid & Acadia Pharma
Can’t sell ACAD stock just because third quarter Nuplazid sales are likely poor. Not when Gilead (GILD), Pfizer (PFE), Biogen Idec (BIIB) and many others are likely suitors.